TURKU, FINLAND / ACCESS Newswire / March 9, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel ...
The Annual Report 2025 published did not contain the auditor's report. This has been corrected in this version. TURKU, FINLAND / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE ...
TURKU, FI / ACCESS Newswire / March 2, 2026 / Faron Pharmaceuticals Ltd (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, ...
SUSPENSION OF TRADING: FARON PHARMACEUTICALS LTD. Trading in the shares of Faron Pharmaceuticals Ltd. was suspended on the Nasdaq First North Growth Market Finland today at 9:39 EET. The company will ...
Median overall survival (mOS) with bexmarilimab and azacitidine in relapsed/refractory (r/r) HR-MDS patients reached 14.5 months (increased from 13.4 months observed earlier), a significant ...
Building on the clinical results of the BEXMAB trial, the IIT aims to evaluate bexmarilimab with an oral HMA backbone to further strengthen evidence of its efficacy in research participants with ...
Study conducted in a collaboration between MEDSIR and University Hospital Vall d'Hebron to evaluate bexmarilimab plus standard-of-care doxorubicin in a high-unmet-need frontline setting. The IIT is ...
TURKU, FINLAND / ACCESS Newswire / March 9, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunother ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results